Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-06-20 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
전환가액의조정(제6회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing regarding the adjustment of the conversion price for convertible bonds (6th series) issued by Cha Biotech. It details the change in conversion price, the number of convertible shares, and the calculation methodology based on market price fluctuations. This type of disclosure regarding capital structure changes, specifically related to convertible debt instruments, falls under the 'Capital/Financing Update' category.
2022-06-20 Korean
신주인수권행사가액의조정(제7회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from Cha Biotech regarding the adjustment of the exercise price of warrants (신주인수권행사가액의 조정). It details the change in exercise price, the number of exercisable shares, and the calculation methodology based on market price fluctuations. This type of disclosure relates to capital structure changes and financing instruments, which falls under the 'Share Issue/Capital Change' category.
2022-06-20 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed under the Capital Markets Act in South Korea. This type of filing is used to disclose significant changes in share ownership by major shareholders and their special related parties. In the context of the provided categories, this document fits the definition of a 'Major Shareholding Notification' (MRQ), which tracks changes in significant share ownership levels.
2022-06-15 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is an official announcement regarding the scheduling and logistics of an Investor Relations (IR) meeting (기업설명회). It provides the date, time, location (Zoom), purpose, and agenda for the upcoming event. Since this is an announcement of an event rather than the presentation slides themselves or a financial report, and it does not fit into specific categories like 'Call Transcript' or 'Annual Report', it is classified as a Regulatory Filing (RNS) as it serves as a formal notice to the market.
2022-05-16 Korean
분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Cha Biotech (차바이오텍) for the period ending March 31, 2022. It contains detailed financial statements, business operations, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). It is not an announcement of a report, as it contains the full substantive content. Q1 2022
2022-05-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and special relationships of major shareholders (Cha Kwang-yul and related parties) in the company 'Cha Biotech'. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-05-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.